Prostaglandylinositol cyclic phosphate (cPIP): a novel second messenger of insulin action. Comparative analysis of two kinds of "insulin mediators".
Insulin induces a broad spectrum of effects over a wide time interval. It also stimulates the phosphorylation of some cellular proteins, while decreasing the state of phosphorylation of others. These observations indicate the presence of different, but not necessarily mutually exclusive, pathways of insulin action. One well-known pathway represents a phosphorylation cascade initiated by the tyrosine kinase activity of the insulin receptor followed by involvement of different MAP-kinases. Another pathway suggests the existence of low molecular weight insulin mediators whose synthesis and/or release is initiated by insulin. Comparable analysis of two kinds of insulin mediators, namely inositolphosphoglycans and prostaglandylinositol cyclic phosphate (cPIP), has been carried out. It has been shown that the expression of a number of enzymes, such as phospholipase A(2), phospholipase C, cyclo-oxygenase and IRS-1-like enzyme, could regulate the biosynthesis of cPIP in both normal and diabetes-related conditions. Data on the activity of a key enzyme of cPIP biosynthesis termed cPIP synthase (IRS-1-like enzyme) in various monkey tissues before and twice during an euglycemic hyperinsulinemic clamp have been presented. It has been concluded that in vivo insulin increases cPIP synthase activity in both liver and subcutaneous adipose tissue of lean normal monkeys. It has been also suggested that abnormal production of cPIP could be related to several pathologies including glucocorticoid-induced insulin resistance and diabetic embryopathy. Further studies on cPIP and other types of insulin mediators are necessary to aid our understanding of insulin action.
Shashkin
P N
PN
Obesity and Diabetes Research Center, Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. pshashkin@hotmail.com
Wasner
H K
HK
Ortmeyer
H K
HK
Hansen
B C
BC
D000818:Animals; D019729:Carbon-Oxygen Ligases / Q000378:metabolism; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology*; D055504:Insulin Receptor Substrate Proteins; D010741:Phospholipases A / Q000378:metabolism; D010750:Phosphoproteins / Q000502:physiology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011458:Prostaglandins E / Q000378:metabolism*; D011972:Receptor, Insulin / Q000378:metabolism; D015290:Second Messenger Systems; D010738:Type C Phospholipases / Q000378:metabolism
C526292:IRS1 protein, human; D007295:Inositol Phosphates; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D010750:Phosphoproteins; D011458:Prostaglandins E; C052775:prostaglandin-inositol cyclic phosphate; D011451:Prostaglandin-Endoperoxide Synthases; D011972:Receptor, Insulin; D010741:Phospholipases A; D010738:Type C Phospholipases; D019729:Carbon-Oxygen Ligases; C110935:prostaglandylinositol cyclic phosphate synthetase